Redhawk Wealth Advisors Inc. Has $3.27 Million Holdings in Cencora, Inc. (NYSE:COR)

Redhawk Wealth Advisors Inc. lifted its holdings in Cencora, Inc. (NYSE:COR) by 4.0% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,747 shares of the company’s stock after acquiring an additional 455 shares during the period. Redhawk Wealth Advisors Inc.’s holdings in Cencora were worth $3,267,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. JFS Wealth Advisors LLC grew its stake in shares of Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after acquiring an additional 46 shares in the last quarter. Banque Transatlantique SA acquired a new stake in Cencora during the fourth quarter worth about $29,000. SBI Securities Co. Ltd. acquired a new stake in Cencora during the fourth quarter worth about $30,000. Kentucky Trust Co acquired a new stake in Cencora during the fourth quarter worth about $33,000. Finally, WASHINGTON TRUST Co grew its stake in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after buying an additional 46 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Up 0.1%

COR stock opened at $284.32 on Wednesday. The stock has a market capitalization of $55.11 billion, a P/E ratio of 40.44, a price-to-earnings-growth ratio of 1.31 and a beta of 0.58. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 12 month low of $218.65 and a 12 month high of $309.35. The firm has a 50-day moving average price of $286.28 and a 200-day moving average price of $260.81.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The business had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. During the same period last year, the company earned $3.80 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.77%. The ex-dividend date of this dividend was Friday, May 16th. Cencora’s payout ratio is currently 25.52%.

Insider Activity

In other Cencora news, EVP Elizabeth S. Campbell sold 4,127 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the transaction, the executive vice president now owns 14,665 shares in the company, valued at approximately $3,934,326.20. This trade represents a 21.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the firm’s stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the transaction, the chairman now owns 315,913 shares of the company’s stock, valued at approximately $89,027,442.53. The trade was a 4.41% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,253 shares of company stock valued at $10,582,297. Insiders own 10.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on COR. UBS Group increased their price objective on shares of Cencora from $298.00 to $335.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. Bank of America increased their price objective on shares of Cencora from $270.00 to $285.00 and gave the stock a “neutral” rating in a research note on Friday, April 11th. Robert W. Baird increased their price objective on shares of Cencora from $314.00 to $350.00 and gave the stock an “outperform” rating in a research note on Thursday, May 8th. Wells Fargo & Company upgraded shares of Cencora from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Finally, Citigroup increased their price objective on shares of Cencora from $330.00 to $355.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $306.91.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.